精确再程放疗处方吸收剂量与分次数的支持工具(PRISTIN)
本研究开发了一种基于形变配准和生物有效剂量(BED)体素级计算的再程放疗支持工具,用于确定再程放疗的处方吸收剂量和分次数。通过两例患者三个场景的计算机模拟验证,工具可计算出满足关键危及器官(OAR)累积BED约束的处方方案,提示其有助于精确再程放疗的剂量分次选择。
要点
- 工具通过形变配准和体素级BED计算,考虑初始照射的恢复,评估OAR累积BED。
- 利用累积BED-体积直方图确定再程放疗的处方吸收剂量和分次数。
- 两例患者三场景模拟验证了工具可行性,但需进一步临床验证。
核心结论
- 该工具被认为有助于找到再程放疗中靶区最合适的处方吸收剂量和分次数。
研究设计与样本
- 方法学开发与计算机模拟验证研究,使用2例患者的3个场景进行验证。
主要发现
- 场景1:右肺门CTV2给予57 Gy/22 Fr时,最大CBEDα/β=2为124.078 Gy,全肺实质(排除大体肿瘤体积)平均CBEDα/β=2为18.332 Gy。
- 场景2:建议靶区给予44.152 Gy/7 Fr最为合适。
- 场景3:推荐靶区质子治疗71.675 Gy/30 Fr,复发部位附近主动脉最大CBEDα/β=2为145.796 Gy,CBEDα/β=2≥100 Gy的体积为0.800 cm3,均在约束范围内。
关键数值与推荐
- 场景1:右肺门CTV2 57 Gy/22 Fr,最大CBEDα/β=2 124.078 Gy,全肺实质平均CBEDα/β=2 18.332 Gy。
- 场景2:靶区44.152 Gy/7 Fr为最合适。
- 场景3:靶区质子治疗71.675 Gy/30 Fr,主动脉最大CBEDα/β=2 145.796 Gy,CBEDα/β=2≥100 Gy体积0.800 cm3。
临床怎么用
- 可用于再程放疗前评估OAR累积BED,辅助制定个体化处方剂量和分次数。
局限性
- 仅在两例患者的三个场景中进行计算机模拟验证,尚未经临床实践验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to develop a supporting tool to calculate the most appropriate prescribing absorbed dose and number of fractions for precise reirradiation. METHODS AND MATERIALS: After deformable image registration of the initial computed tomography to the computed tomography at reirradiation, an initial biological effective dose (BED) taking into account the recovery from the initial irradiation is calculated voxel-by-voxel for each organ at risk (OAR). Using a commercial radiation therapy planning system, the clinical target volume for reirradiation (CTV2) is made. Keeping the BEDtumor's α/β to CTV2, cumulative BEDOAR's α/β(CBEDOAR's α/β) in each voxel of critical OARs is calculated by changing the number of fractions in a stepwise process. The most appropriate prescribing absorbed dose to the target and the number of fractions in reirradiation is determined by using CBEDOAR's α/β-volume histogram for critical OARs. The function of the tool was validated in silico using 3 scenarios in 2 patients: a patient with a lung cancer at the peripheral lung parenchyma and at the hilar lymphatic region at different times, and in a patient with a metastatic internal mammary lymph node relapsed after postoperative radiation therapy for breast cancer. RESULTS: In scenario 1, giving 57 Gy in 22 fractions (57 Gy/22 Fr) to the CTV2 at the right hilum, the maximum CBEDα/β=2 was 124.078 Gy, and the mean CBEDα/β=2 of the whole lung parenchyma excluding gross tumor volume was 18.332 Gy. In scenario 2, 44.152 Gy/7 Fr to the target was suggested to be most appropriate. In scenario 3, 71.675 Gy/30 Fr proton therapy to the target was recommended in which the maximum CBEDα/β=2 in the aorta near the recurrence site was 145.796 Gy, and the volume of CBEDα/β=2 ≥ 100 Gy was 0.800 cm3, both are within the constraints. CONCLUSIONS: The tool was suggested to be useful to find the most appropriate prescribing absorbed dose to the target as well as the number of fractions for precise reirradiation.
引用
- Hagiwara M, Suzuki R, Takao S, et al. A Precise Reirradiation Supporting Tool Initiative (PRISTIN) for Prescribing Absorbed Dose and Number of Fractions in Reirradiation. Adv Radiat Oncol. 2025. PMID: 41140301. doi:10.1016/j.adro.2025.101904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。